OpenBench

OpenBench specializes in early-stage, structure-based small molecule hit discovery using a proprietary AI-driven platform. The company operates on a success-driven model: clients only pay for potent, developable compounds that meet pre-set criteria. OpenBench claims high success rates in identifying novel, high-quality hits, including for first-in-class and allosteric targets, but does not manage its own clinical pipeline or report clinical results as it is a CRO/platform provider. Its main offering is a technology platform for structure-based virtual screening, serving as a CRO for other biotechs and academic groups. The company does not publicly disclose specific drug targets, indications, or developed assets, as it serves partners rather than owning pipeline assets.